牛牛AI助理已提取核心訊息
On December 31, 2023, a Schedule 13G was filed with the SEC by Ameriprise Financial, Inc. and several associated entities, collectively referred to as the Ameriprise Entities, regarding their holdings in Altimmune, Inc. The filing indicates that Ameriprise Financial, Inc., along with TAM UK International Holdings Limited, Threadneedle Holdings Limited, TAM UK Holdings Limited, Threadneedle Asset Management Holdings Limited, TC Financing Ltd, Threadneedle Asset Management Limited, and Threadneedle Investment Services Limited, have a shared voting and dispositive power over a significant number of shares in Altimmune. Specifically, Ameriprise Financial, Inc. reported shared voting and dispositive power over 4,183,682 shares, representing 7.79% of the class, while the other entities each reported shared power over 4,013,211 shares, representing 7.47% of the class. The entities are organized under the laws of Delaware, England, and Wales. The filing was certified by Michael G. Clarke, Senior Vice President of Ameriprise Financial, Inc., on February 14, 2024, stating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune, Inc.
On December 31, 2023, a Schedule 13G was filed with the SEC by Ameriprise Financial, Inc. and several associated entities, collectively referred to as the Ameriprise Entities, regarding their holdings in Altimmune, Inc. The filing indicates that Ameriprise Financial, Inc., along with TAM UK International Holdings Limited, Threadneedle Holdings Limited, TAM UK Holdings Limited, Threadneedle Asset Management Holdings Limited, TC Financing Ltd, Threadneedle Asset Management Limited, and Threadneedle Investment Services Limited, have a shared voting and dispositive power over a significant number of shares in Altimmune. Specifically, Ameriprise Financial, Inc. reported shared voting and dispositive power over 4,183,682 shares, representing 7.79% of the class, while the other entities each reported shared power over 4,013,211 shares, representing 7.47% of the class. The entities are organized under the laws of Delaware, England, and Wales. The filing was certified by Michael G. Clarke, Senior Vice President of Ameriprise Financial, Inc., on February 14, 2024, stating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune, Inc.
2023 年 12 月 31 日，Ameriprise Financial, Inc. 和幾家關聯實體（統稱爲 Ameriprise 實體）就其在 Altimmune, Inc. 的股份向美國證券交易委員會提交了附表13G。該文件顯示，Ameriprise Financial, Inc. 以及TAM 英國國際控股有限公司、TAM 英國控股有限公司、Threadneedle 資產管理控股有限公司、TC 融資有限公司、Threadneedle 資產管理有限公司和 Threadneedle 投資服務有限公司，擁有共同投票權和決定權控制Altimmune的大量股份。具體而言，Ameriprise Fi...展開全部
2023 年 12 月 31 日，Ameriprise Financial, Inc. 和幾家關聯實體（統稱爲 Ameriprise 實體）就其在 Altimmune, Inc. 的股份向美國證券交易委員會提交了附表13G。該文件顯示，Ameriprise Financial, Inc. 以及TAM 英國國際控股有限公司、TAM 英國控股有限公司、Threadneedle 資產管理控股有限公司、TC 融資有限公司、Threadneedle 資產管理有限公司和 Threadneedle 投資服務有限公司，擁有共同投票權和決定權控制Altimmune的大量股份。具體而言，Ameriprise Financial, Inc.報告了對4,183,682股股票的共享投票權和處置權，佔該類別的7.79％，而其他實體則報告了對4,013,211股股票的共享權力，佔該類別的7.47％。這些實體根據特拉華州、英格蘭和威爾士的法律組建。該文件於2024年2月14日獲得Ameriprise Financial, Inc.高級副總裁邁克爾·克拉克的認證，稱這些股票是在正常業務過程中收購的，不是爲了改變或影響Altimmune, Inc.的控制權。
有用
沒用